CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size

Conditions

Endometriosis

Brief summary

Reduction in the size of endometriotic lesions assessed by transvaginal ultrasound/magnetic resonance imaging (MRI)/laparoscopy., Relief of pelvic pain measured by visual analogue scale (VAS) before and after treatment.

Detailed description

Demographic and clinical characteristics: Age, BMI, ethnicity, comorbidities (diabetes, hypertension, immunosuppression, smoking), Eznian classification (a system designed to describe deep infiltrating endometriosis (DIE) in a detailed and topographical manner, complementing the limitations of other classifications such as ASRM., Changes in serum prolactin and VEGF levels as pre- and post-treatment angiogenic markers., Impact on other symptoms associated with endometriosis, such as irregular bleeding and infertility, assessed clinically and through hormonal analysis (FSH, LH, estradiol, AMH)., Safety profile: frequency and type of adverse effects related to cabergoline (nausea, vomiting, dizziness)., Quality of life measured using specific questionnaires such as the Endometriosis Health Profile (EHP-30).

Related papers

No related papers found yet.

Interventions

DRUGSibilla diario 2 mg / 0

DRUG03 mg comprimidos recubiertos con película EFG

DRUGDostinex 0.5 mg Tablets

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Reduction in the size of endometriotic lesions assessed by transvaginal ultrasound/magnetic resonance imaging (MRI)/laparoscopy., Relief of pelvic pain measured by visual analogue scale (VAS) before and after treatment.	—

Secondary

Measure	Time frame
Demographic and clinical characteristics: Age, BMI, ethnicity, comorbidities (diabetes, hypertension, immunosuppression, smoking), Eznian classification (a system designed to describe deep infiltrating endometriosis (DIE) in a detailed and topographical manner, complementing the limitations of other classifications such as ASRM., Changes in serum prolactin and VEGF levels as pre- and post-treatment angiogenic markers., Impact on other symptoms associated with endometriosis, such as irregular bleeding and infertility, assessed clinically and through hormonal analysis (FSH, LH, estradiol, AMH)., Safety profile: frequency and type of adverse effects related to cabergoline (nausea, vomiting, dizziness)., Quality of life measured using specific questionnaires such as the Endometriosis Health Profile (EHP-30).	—

Measure

Time frame

Demographic and clinical characteristics: Age, BMI, ethnicity, comorbidities (diabetes, hypertension, immunosuppression, smoking), Eznian classification (a system designed to describe deep infiltrating endometriosis (DIE) in a detailed and topographical manner, complementing the limitations of other classifications such as ASRM., Changes in serum prolactin and VEGF levels as pre- and post-treatment angiogenic markers., Impact on other symptoms associated with endometriosis, such as irregular bleeding and infertility, assessed clinically and through hormonal analysis (FSH, LH, estradiol, AMH)., Safety profile: frequency and type of adverse effects related to cabergoline (nausea, vomiting, dizziness)., Quality of life measured using specific questionnaires such as the Endometriosis Health Profile (EHP-30).

—

Countries

Spain

Outcome results

None listed